During this session you will learn about S1P receptor modulators and anti-integrin therapy. Safety, efficacy and when to consider use of these therapies in the treatment of patients with UC and Crohn's disease will be covered.
This session is supported by an independent educational grant from Bristol Myers Squibb.
Learning Objectives:
Summarize key efficacy and safety data for new and emerging S1P receptor modulators and anti-integrins in the treatment of IBD
Leverage the benefits of S1P receptor modulator treatment in appropriate patients with UC
Demonstrate appropriate use of anti-integrin therapy in patients with IBD